Candriam S.C.A. Has $84.99 Million Stock Holdings in Danaher Corporation $DHR

Candriam S.C.A. boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 15.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 402,524 shares of the conglomerate’s stock after buying an additional 53,638 shares during the period. Candriam S.C.A. owned approximately 0.06% of Danaher worth $84,986,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of DHR. Nuveen LLC acquired a new position in Danaher during the first quarter worth $833,941,000. GAMMA Investing LLC raised its holdings in Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock worth $383,524,000 after buying an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock worth $376,347,000 after acquiring an additional 1,601,800 shares in the last quarter. Invesco Ltd. grew its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Danaher by 460.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock worth $309,558,000 after acquiring an additional 1,107,998 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reiterated a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research report on Friday, July 11th. HSBC reduced their price target on shares of Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Finally, Robert W. Baird increased their price target on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Price Performance

NYSE DHR opened at $212.2350 on Wednesday. The company has a market cap of $151.97 billion, a PE ratio of 45.16, a price-to-earnings-growth ratio of 2.92 and a beta of 0.73. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm’s 50-day simple moving average is $200.33 and its two-hundred day simple moving average is $199.54.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.